Erectile Dysfunction Clinical Trial
Official title:
A Randomized, Placebo Controlled, Double Blind, Multicenter Therapeutic Exploratory Clinical Study for the Evaluation of the Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction
Verified date | June 2015 |
Source | Pusan National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Institutional Review Board |
Study type | Interventional |
This is an exploratory clinical study to presume the optimum usage and dosage for a therapeutic confirmatory study by evaluating the efficacy and safety of Avanafil 50mg, 100mg, 200mg or placebo administered orally in patients with erectile dysfunction. In conclusions, Patients with erectile dysfunction (ED) were administered placebo, Avanafil 50mg, 100mg or 200mg 30 minutes before sexual intercourse for 8 weeks.
Status | Completed |
Enrollment | 159 |
Est. completion date | September 2008 |
Est. primary completion date | September 2008 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 19 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. The male subjects who were aged 19 ~ 70 with history of erectile dysfunction for at least 6 months duration 2. The subjects who had had stable monogamous relationships with their female partners 3. Their partners were free from pregnancy and lactation and well prevent conception 4. The subjects who were judged to be suitable to the clinical study in consequence of screening test 5. The subjects who consented to participate in the clinical study in writing 6. The subjects who attempted sexual intercourses at least 4 times in separate days during 4 weeks' free run-in period, and whose failure rate was over 50%. 7. The subjects whose point were between 11 and 25 in EF domain of IIEF after 4 weeks' free run-in period Exclusion Criteria: The following cases were excluded from this clinical study. 1. The subjects who had spinal cord injury or who underwent radical prostatectomy 2. The subjects whose penises were anatomically deformed (Ex: server penile fibrosis, and Peyronie's disease) 3. The subjects who had erectile dysfunction due to neurogenic or endocrine cause (hyperprolactinemia, low serum testosterone levels, etc.) - Hyperprolactinemia: serum prolactin over 3 times higher than the upper limit - Low Testosterone: serum total testosterone less than the lower limit 4. The subjects who had uncontrolled major psychiatric disorder and did not accept therapies (includes major depressions and schizophrenia) or had significant neurological abnormalities (neurovascular disorder) 5. The subjects who underwent cancer chemotherapy within 1 year 6. The subjects who were addicted to alcohol or who had continuously misused dependent drugs 7. The subjects who had hepatic dysfunction or renal dysfunction as in the following: - Hepatic Dysfunction: GOT and GPT (glutamate-pyruvate transaminase) were three times higher than the upper limit - Renal Dysfunction: serum creatinine was over 2.0mg/dl 8. The subjects who had uncontrollable diabetes (FPG>180mg/dL) 9. The subjects who had proliferative diabetic retinopathy 10. The subjects who suffered from stroke, transient ischemic attacks, myocardial infarction, heart failure that needed to be medically treated, unstable angina or fatal arrhythmia or who underwent coronary artery bypass graft within 6 months 11. The subjects had serious hypotension (SBP/DBP(diastolic blood pressure) is less than 90/50mmHg in a sitting posture) or uncontrollable severe hypertension (SBP/DBP is over 170/100mmHg in a sitting posture) 12. The subjects who had hematological disorders that was likely to be developed into priapism such as sickle cell disease, multiple myeloma, leukemia 13. The subjects who had retinitis pigmentosa 14. The subjects who suffered from serious GI bleeding disorder within 1 year 15. The subjects who took Viagra®, Cialis®, Levitra®, Mvix® and others within 2 weeks before the clinical study 16. The subjects who had taken the following drugs ? Nitrate/Nitric oxide(NO) donors(ex. Nitroglycerin, isosorbide mononitrate, amyl nitrate/nitrite, sodium nitroprusside) ? Androgens(ex testosterone), anti-androgen, trazodone ? Anticoagulant (excludes antiplatelet drugs) ? Erythromycin, itraconazole, ketoconazole, cimetidine, ritonavir, saquinavir, amprenavir, indinavir and nelfinavir that greatly affects CYP3A4 (cytochrome P450 isoenzyme 3A4) 17. The subjects who had history of hypersensitivity to the PDE(phosphodiesterase)-5 inhibitors or whose erectile dysfunction was not improved 18. The subjects who had hypoactive sexual desire 19. The subjects who had no intention of having sexual intercourses 4 times in separate days during 4 weeks' free run-in period 20. The subjects who took other study drugs within 30 days before this clinical study 21. The subjects who were judged to be unsuitable to the clinical study by other reasons |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Department of Urology, Pusan National University Hospital | Busan |
Lead Sponsor | Collaborator |
---|---|
Pusan National University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of erectile (EF) domain score in the international index of erectile function (IIEF) questionnaire | Week 4 and 8 | Yes | |
Secondary | The change of success rate for SEP (Sexual encounter profile) questionnaire 2,3,4 and 5 | Week 4 and 8 | Yes | |
Secondary | The change of score in orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction domains in international index of erectile function (IIEF) | Week 4 and 8 | Yes | |
Secondary | The change of score in the international index of erectile function (IIEF) questionnaire 3 and 4 | Week 4 and 8 | Yes | |
Secondary | Improvement of erection on the GEAQ (Global Efficacy Assessment Question) questionnaire | The GEAQ question, 'Has the treatment you have been over the past 8weeks improved your erections?' | Week 4 and 8 | Yes |
Secondary | Normal erectile function (IIEF EF domain score = 26) rate | Week 4 and 8 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 |